EMA Phased Review: Evidence Deadlines and Launch Investment

Week of 12–18 October 2026 · Evidence checked on 18 October · 5-minute read

Rasonque’s phased review shows why a faster regulatory timetable belongs in the investment plan. EU joint clinical assessment deadlines are linked to regulatory milestones; national access still follows its own route.

A launch plan that relies on a year of regulatory review to finish its evidence and market preparation needs a faster-review scenario.

On 15 October, the CHMP recommended authorising Revolution Medicines’ Rasonque (daraxonrasib) for adults with previously treated metastatic pancreatic cancer. EMA began reviewing data in phases in early July, before the complete application arrived, and reports an assessment time under 150 days. Its standard comparison is up to 210 active days and usually around a year overall, including company response time. Those measures should not be treated as a precise calendar saving. EMA announcement.

The European Commission’s authorisation decision remains pending as of 18 October. EMA says that decision will be fast-tracked and that further phased reviews will be considered case by case. Rasonque status; EMA announcement.

My take: an earlier regulatory milestone can bring evidence spending forward. Whether it also brings revenue forward depends on supply, market readiness and national access.

The signal: linked evidence deadlines, separate access decisions

Rasonque falls within the EU Health Technology Assessment Regulation. IQWiG lists its joint clinical assessment (JCA), conducted with the Danish Medicines Council, as starting in July 2026, with expected completion “tbd”. IQWiG JCA list.

The JCA has a separate remit and deadlines tied to regulatory milestones. Three obligations matter:

Milestone	Responsible party	Deadline
Submit the JCA dossier	Developer	At the latest 45 days before the envisaged CHMP opinion date.
Finalise the revised draft reports	JCA Subgroup	By the Commission’s authorisation decision.
Endorse the reports	HTA Coordination Group	No later than 30 days after that Commission decision.

Sources: Regulation (EU) 2021/2282, Articles 10(1) and 11(1)(a); Implementing Regulation (EU) 2024/1381, Article 15(2).

The implementing rules normally allow 100 days from the first dossier request, or 60 days for accelerated assessment and specified new-indication variations. Phased review is not itself listed as a trigger for that shorter window. The actual request and envisaged regulatory timetable must guide the plan. Article 12(2)–(3).

National access follows a separate timetable. Pricing and reimbursement remain national decisions; in Germany, the JCA informs the AMNOG benefit assessment rather than replacing it. EMA; IQWiG.

The operator’s take: price the earlier commitment

If an earlier opinion brings the developer’s dossier deadline forward, comparator analyses and evidence-gap work may need funding sooner, before the regulator has concluded. Hiring and inventory require their own country scenarios: an earlier opinion does not automatically justify moving every commitment forward. [Inference]

That is the trade-off for the launch committee. Commit early and some expenditure may be unrecoverable if the outcome changes. Commit late and the company may be unable to use an earlier authorisation. The decision is how much readiness to buy, when, and with what ability to change course.

Revolution Medicines reported US launch readiness in August and said it was accelerating global commercial capabilities ahead of potential international approvals. That makes international readiness a concrete planning question. Q2 2026 results, Exhibit 99.1.

Three decisions before the next launch review

Price a faster-review scenario. Where phased review is a realistic possibility, model an earlier CHMP date alongside the base case. Identify which evidence spending must move and what delay would cost. For each priority market, stage hiring, supply and promotion against its regulatory and access milestones.

Prepare before formal scoping. Map plausible member-state comparator needs and analytical gaps early. Reserve the resources to address them. The JCA Subgroup finalises the scope; the company prepares for it and works to the dates in the actual submission request.

Name one owner of the integrated plan. Give one leader responsibility for dependencies, resources and escalation across regulatory, JCA and national work. Specialists retain their submission responsibilities. Track confirmed dates separately from forecasts. Commercial leadership owns the resource choices and market sequence.

What to watch?

Watch the Commission decision, the JCA endorsement date and EMA’s selection of further phased-review candidates. Then watch whether national access turns an earlier authorisation into earlier reimbursed use.

For the next launch review: if your lead asset’s CHMP opinion arrived months earlier than planned, which spending decisions would you need to have taken already?

Price the earlier commitment before you count the earlier revenue.

Independent analysis by Piotr Wrzosinski. Developed with AI assistance for research, source checking and editing. Sources are linked; analysis and recommendations are the author’s interpretation of public evidence. Views are personal.